Clinical trial
Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer
NCT00003351 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00003351 |
|---|---|
| Title | Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer |
| Official title | Randomized Phase II Trial of Irinotecan (CPT-11) In Patients With Refractory Metastatic Breast Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride |
| Enrollment | 104 |
| Start date | Aug 1, 1998 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Mar 1, 2004 |
| Last update posted | Jul 14, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: